Sophia Scharl1, Tim Sprötge2, Michael Gerken2, Anton Scharl3, Olaf Ortmann4, Oliver Kölbl5, Monika Klinkhammer-Schalke2, Thomas Papathemelis6. 1. Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany. sophiascharl@yahoo.de. 2. Tumor Center, Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany. 3. Oncology Competence Center, Klinik Bad Trissl, Oberaudorf, Germany. 4. Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany. 5. Department of Radiation Oncology, University Medical Centre Regensburg, Regensburg, Germany. 6. Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany.
Abstract
PURPOSE: Data from randomized controlled trials in high-grade endometrial cancer are scarce due to its low prevalence. Therefore, guideline recommendations in this cancer subtype rely on relatively few randomized trials and data from retrospective studies. The aim of this study was to evaluate the benefits from guideline-concordant therapy in high-grade endometrial cancer in a real-world patient group. METHODS: The effect of treatment according to German S3 guidelines and the former S2k guideline on overall survival (OS) and recurrence-free survival (RFS) was evaluated in a cohort of 293 high-grade endometrial cancer patients. RESULTS: Treatment concordant with the S3 guideline significantly improved OS (HR 0.623, CI 0.420-0.923, p = 0.018) and RFS (HR 0.578, CI 0.387-0.863, p = 0.007). Treatment concordant with the S2k guideline did not result in a significantly higher OS (HR 0.783, CI 0.465-1.316, p = 0.335) or RFS (HR 0.741, CI 0.347-1.740, p = 0.242). CONCLUSION: Therapy according to the German S3 guideline improved OS and RFS in univariate as well as multivariate analysis in this cohort of high-grade endometrial cancer patients.
PURPOSE: Data from randomized controlled trials in high-grade endometrial cancer are scarce due to its low prevalence. Therefore, guideline recommendations in this cancer subtype rely on relatively few randomized trials and data from retrospective studies. The aim of this study was to evaluate the benefits from guideline-concordant therapy in high-grade endometrial cancer in a real-world patient group. METHODS: The effect of treatment according to German S3 guidelines and the former S2k guideline on overall survival (OS) and recurrence-free survival (RFS) was evaluated in a cohort of 293 high-grade endometrial cancer patients. RESULTS: Treatment concordant with the S3 guideline significantly improved OS (HR 0.623, CI 0.420-0.923, p = 0.018) and RFS (HR 0.578, CI 0.387-0.863, p = 0.007). Treatment concordant with the S2k guideline did not result in a significantly higher OS (HR 0.783, CI 0.465-1.316, p = 0.335) or RFS (HR 0.741, CI 0.347-1.740, p = 0.242). CONCLUSION: Therapy according to the German S3 guideline improved OS and RFS in univariate as well as multivariate analysis in this cohort of high-grade endometrial cancer patients.
Authors: Ashley S Felix; Eric M McLaughlin; Bette J Caan; David E Cohn; Garnet L Anderson; Electra D Paskett Journal: Int J Cancer Date: 2019-10-31 Impact factor: 7.396
Authors: L Schwentner; R Wolters; K Koretz; M B Wischnewsky; R Kreienberg; R Rottscholl; A Wöckel Journal: Breast Cancer Res Treat Date: 2011-12-29 Impact factor: 4.872
Authors: Sophia Scharl; Thomas Papathemelis; Karin Kronberger; Michael Gerken; Anton Scharl; Oliver Kölbl; Monika Klinkhammer-Schalke Journal: Arch Gynecol Obstet Date: 2018-02-07 Impact factor: 2.344
Authors: Hiba Z Ahmed; Yuan Liu; Kelli O'Connell; Maaz Z Ahmed; Richard J Cassidy; Theresa W Gillespie; Pretesh Patel; Rathi N Pillai; Madhusmita Behera; Conor E Steuer; Taofeek K Owonikoko; Suresh S Ramalingam; Walter J Curran; Kristin A Higgins Journal: Clin Lung Cancer Date: 2017-04-28 Impact factor: 4.785
Authors: Marcus E Randall; Virginia Filiaci; D Scott McMeekin; Vivian von Gruenigen; Helen Huang; Catheryn M Yashar; Robert S Mannel; Jae-Weon Kim; Ritu Salani; Paul A DiSilvestro; James J Burke; Thomas Rutherford; Nick M Spirtos; Keith Terada; Penny R Anderson; Wendy R Brewster; William Small; Carol A Aghajanian; David S Miller Journal: J Clin Oncol Date: 2019-04-17 Impact factor: 50.717
Authors: Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Alessandro Colombo; Anthony Fyles; Marie-Helene Baron; Ina M Jürgenliemk-Schulz; Henry C Kitchener; Hans W Nijman; Godfrey Wilson; Susan Brooks; Silvestro Carinelli; Diane Provencher; Chantal Hanzen; Ludy C H W Lutgens; Vincent T H B M Smit; Naveena Singh; Viet Do; Romerai D'Amico; Remi A Nout; Amanda Feeney; Karen W Verhoeven-Adema; Hein Putter; Carien L Creutzberg Journal: Lancet Oncol Date: 2018-02-12 Impact factor: 41.316
Authors: Clara Taubenhansl; Olaf Ortmann; Michael Gerken; Elisabeth C Inwald; Monika Klinkhammer-Schalke Journal: Arch Gynecol Obstet Date: 2019-11-20 Impact factor: 2.344
Authors: E C Inwald; O Ortmann; F Zeman; M Koller; F Hofstädter; M Gerstenhauer; M Klinkhammer-Schalke Journal: Biomed Res Int Date: 2014-03-20 Impact factor: 3.411